• be ≥ 18 years of age on the day of signing of informed consent.

• confirmed Stage 4 NSCLC (squamous or non-squamous) and be considered for standard of care.

• have confirmation that mutation-directed therapy is not indicated (documentation of absence of tumor activating mutations/fusions that are approved for first line therapy).

• have at least 1 lesion with measurable disease at Baseline according to RECIST 1.1 as determined by the local site Investigator/radiology assessment.

• have not received prior systemic treatment for advanced/metastatic NSCLC.

• have an ECOG Performance Status of 0 to 1.

• have adequate organ function.